Description
Edesa will complete a pre-clinical study, and Phase II trials to evaluate the safety and efficacy of an antibody treatment (EB05) in hospitalized COVID-19 patients.
Amendment chain · 2 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $14,054,000 at start, $14,053,500 after amendment #1 (−$500).
- #02020-04-23$14,054,000
- #12026-03-31$14,053,500-$500
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2020-04-23(start date) | $14,054,000 | — | Edesa will complete a pre-clinical study, and Phase II trials to evaluate the safety and efficacy of an antibo… |
| #1 amendment | 2026-03-31 | $14,053,500 | −$500 | Edesa will complete a pre-clinical study, and Phase II trials to evaluate the safety and efficacy of an antibo… |
Related records · 7
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (business number 815678123)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 033-2023-2024-Q3-514239 | Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada · SIF Stream 1- R&D | $23,000,000 | FY2024 |
| 172-2020-2021-Q1-950033 | National Research Council Canada | Conseil national de recherches Canada · Innovation Assistance Program | $81,312 | FY2021 |
Other recipients funded under "SIF Stream 1 - R&D" by Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 033-2024-2025-Q2-816194 | Kepler Communications Inc. | FY2025 | $20,000,000 | FY2025 |
| 033-2024-2025-Q1-819661 | Giatec Scientific Inc. | FY2025 | $17,500,000 | FY2025 |
| 033-2024-2025-Q1-820045 | Biotechnologies Aramis Inc. | FY2025 | $40,000,000 | FY2025 |
| 033-2023-2024-Q3-819513 | IBM Canada Limited - IBM Canada Ltée | FY2024 | $24,885,000 | FY2024 |
| 033-2023-2024-Q1-814534 | AVL Fuel Cell Canada Inc. | FY2024 | $15,000,000 | FY2024 |
Cite as: Glassbox record view · Federal grants & contributions · 033-2020-2021-Q4-513437 · retrieved 2026-11-12.